The Economist. A new report on the situation of the pharmaceutical sector worldwide ensures that the development of biosimilar medicines could save up to 98 million euros (110.000 million dollars) in 2020, taking into account the US market and the five most important European markets -Germany , France, Italy, United Kingdom, Spain-
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
